Desing Concept of Tissue Engineered Products for Use in Emergency and Critical Care Medicine

Yoshimitsu Kuroyanagi*^1,2 and Misato Kuroyanagi³

Received: January 20, 2018;   Published: January 25, 2018

DOI: 10.26717/BJSTR.2018.02.000692

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Three types of tissue-engineered products were developed using cell, growth factor, and biomaterial. The first product is a CDS composed of allogeneic fibroblasts combined with a HA and Col spongy sheet. Fibroblast can release various growth factors that are essential for wound healing. HA and Col have a potential to enhance wound healing. This CDS can be cryopreserved for a long period of up to clinical use. The clinical study demonstated that allogeneic CDS is a useful product. The second product is a wound dressing composed of HA and Col containing EGF. EGF has a potential to enhace wound healing. This wound dressing is a freeze-dried spongy sheet, thereby the efficacy of EGF can be kept for a long period of up to clinical use. The clinical study showed that EGF-incorporating wound dressing is a practical product. The third product is an anti-adhesive spongy sheet composed of HA and Col containing EGF. This is also a freeze-dried spongy sheet. The animal study indicated that EGF-incorporating anti-adhesive spongy sheet is a promissing product.

Abbreviations: CES: Cultured Epidermal Substitute, CDS: Cultured Dermal Substitute, CSS: Cultured Skin Substitute, HA: Hyarulonic Acid, Col: Collagen, EGF: Epidermal Growth Factor, VEGF: Vascular Endothelial Growth Factor, HGF: Hepatocyte Growth Factor, BFGF: Basic Fibroblast Growth Factor

Abstract| Introduction| Conclusion| References|